Baseline patient characteristics
| Characteristic . | N = 99 . |
|---|---|
| Median age, y (range) | 64 (33-85) |
| ≥65 y, n (%) | 45 (46) |
| Male sex, n (%) | 66 (67) |
| Histology, n (%) | |
| CLL | 98 (99) |
| SLL | 1 (1) |
| Median time from initial CLL diagnosis to first dose, y (range) | 3.4 (0.1-16.5) |
| Baseline Rai stage, n (%) | |
| I to II | 43 (43) |
| III to IV | 47 (47) |
| Unknown | 9 (9) |
| ECOG PS score, n (%) | |
| 0 | 34 (34) |
| 1 | 65 (66) |
| Patients with cytopenia(s), n (%) | 52 (53) |
| Absolute neutrophil count ≤1.5 × 109/L | 10 (10) |
| Hemoglobin ≤11 g/dL | 38 (38) |
| Platelets ≤100 × 109/L | 28 (28) |
| Presence of B symptoms, n (%) | 21 (21) |
| β2-microglobulin >3.5 mg/L, n/N (%) | 72/93 (77) |
| Bulky disease, n/N (%) | |
| ≥5 cm | 46/99 (46) |
| ≥10 cm | 6/99 (6) |
| Genomic status, n/n (%) | |
| del(11q)* | 19/91 (21) |
| del(17p)† | 9/91 (10) |
| Complex karyotype | 12/66 (18) |
| Unmutated IGHV | 57/92 (62) |
| Mutated TP53 | 9/65 (14) |
| TP53 aberration‡ | 12/68 (18) |
| Characteristic . | N = 99 . |
|---|---|
| Median age, y (range) | 64 (33-85) |
| ≥65 y, n (%) | 45 (46) |
| Male sex, n (%) | 66 (67) |
| Histology, n (%) | |
| CLL | 98 (99) |
| SLL | 1 (1) |
| Median time from initial CLL diagnosis to first dose, y (range) | 3.4 (0.1-16.5) |
| Baseline Rai stage, n (%) | |
| I to II | 43 (43) |
| III to IV | 47 (47) |
| Unknown | 9 (9) |
| ECOG PS score, n (%) | |
| 0 | 34 (34) |
| 1 | 65 (66) |
| Patients with cytopenia(s), n (%) | 52 (53) |
| Absolute neutrophil count ≤1.5 × 109/L | 10 (10) |
| Hemoglobin ≤11 g/dL | 38 (38) |
| Platelets ≤100 × 109/L | 28 (28) |
| Presence of B symptoms, n (%) | 21 (21) |
| β2-microglobulin >3.5 mg/L, n/N (%) | 72/93 (77) |
| Bulky disease, n/N (%) | |
| ≥5 cm | 46/99 (46) |
| ≥10 cm | 6/99 (6) |
| Genomic status, n/n (%) | |
| del(11q)* | 19/91 (21) |
| del(17p)† | 9/91 (10) |
| Complex karyotype | 12/66 (18) |
| Unmutated IGHV | 57/92 (62) |
| Mutated TP53 | 9/65 (14) |
| TP53 aberration‡ | 12/68 (18) |